MedTrace Logo

Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia

NCT02146859 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2018-03-27

No results posted yet for this study

Summary

Background When general anesthesia was performed, neuromuscular blocking agents (NMBAs) are frequently used for facilitate tracheal intubation and keep patient still and relax during surgery. Unfortunately, residual neuromuscular blockade are important complication.

There are many factors that affect neuromuscular blockade and may prolong effect of NMBAs which we already know about that such as body temperature, drugs, some kind of diseases. However there are no recent studies that mention about other factors. The purpose of this study is to find out other factors that affect NMBAs effect to improve patient safety.

Methods The study is a prospective, non-randomized, blinded, observational study.

222 patients will be included in this study and will be performed general anesthesia. Anesthetic technique and agent which are used depend on regular staff. Information of patient will be collected are age, sex, weight, height, ASA classification, anesthetic technique, anesthetic and surgical time, amount of inhalation agent, amount of NMBAs, amount of opioids and reversal agents.

After anesthesia finish, patient will be brought to recovery room and Train Of Four watch® will be placed and record Train Of Four ratio by this research staff. Train Of Four ratio \< 0.9 will be defined as there is residual neuromuscular blockade in this patient.

All patients will be divided into 2 groups: residual blockade group(patient who have train of four \<0.9 after surgery) and no residual blockade group(patient who have train of four \>0.9). All factor of each group will be compared between. Statistical will be analyzed to find significant factor which affect neuromuscular blockade.

Conditions

  • Residual Neuromuscular Blockade

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-01-31
Completion
2017-03-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02146859 on ClinicalTrials.gov